Gabriel Rinnerthaler

8PUBLICATIONS
40CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jun 26, 2026
Reducing breast cancer recurrences with CDK4/6 inhibitor treatment of HR-positive, HER2-negative early stage breast cancer from a societal perspective.

|Mar 07, 2025
Augmenting Insufficiently Accruing Oncology Clinical Trials Using Generative Models: Validation Study.

Samer El Kababji, Nicholas Mitsakakis, Elizabeth Jonker

|Jan 17, 2025
Neoadjuvant atezolizumab in combination with dual HER2 blockade plus epirubicin in women with early HER2-positive breast cancer: the randomized phase 2 ABCSG-52/ATHENE trial.

Gabriel Rinnerthaler, Daniel Egle, Rupert Bartsch

|Jan 11, 2022
Sex-Based Clinical Outcome in Advanced NSCLC Patients Undergoing PD-1/PD-L1 Inhibitor Therapy-A Retrospective Bi-Centric Cohort Study.

David Lang, Anna Brauner, Florian Huemer

|Dec 04, 2021
Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response.

Qing Zhou, Simon P Gampenrieder, Sophie Frantal

|Jun 02, 2021
Prognostic and Predictive Factors in Advanced Head and Neck Squamous Cell Carcinoma.

Teresa Magnes, Sandro Wagner, Dominik Kiem

Pageof 2

Frequent Collaborators

5 joint publications

Richard Greil

3 joint publications

Florian Huemer

3 joint publications

Marija Balic

3 joint publications

Michael Gnant